- Home
- SGMT vs NRO Comparison
SGMT vs NRO Comparison
Compare SGMT & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- NRO
- Stock Information
- Founded
- SGMT 2006
- NRO 2003
- Country
- SGMT United States
- NRO United States
- Employees
- SGMT N/A
- NRO N/A
- Industry
- SGMT
- NRO Finance/Investors Services
- Sector
- SGMT
- NRO Finance
- Exchange
- SGMT Nasdaq
- NRO Nasdaq
- Market Cap
- SGMT 238.7M
- NRO 199.6M
- IPO Year
- SGMT 2023
- NRO N/A
- Fundamental
- Price
- SGMT $8.52
- NRO $3.21
- Analyst Decision
- SGMT Strong Buy
- NRO
- Analyst Count
- SGMT 8
- NRO 0
- Target Price
- SGMT $26.88
- NRO N/A
- AVG Volume (30 Days)
- SGMT 655.0K
- NRO 239.4K
- Earning Date
- SGMT 11-13-2025
- NRO 01-01-0001
- Dividend Yield
- SGMT N/A
- NRO 11.41%
- EPS Growth
- SGMT N/A
- NRO N/A
- EPS
- SGMT N/A
- NRO N/A
- Revenue
- SGMT N/A
- NRO N/A
- Revenue This Year
- SGMT N/A
- NRO N/A
- Revenue Next Year
- SGMT N/A
- NRO N/A
- P/E Ratio
- SGMT N/A
- NRO N/A
- Revenue Growth
- SGMT N/A
- NRO N/A
- 52 Week Low
- SGMT $1.73
- NRO $2.51
- 52 Week High
- SGMT $11.41
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- SGMT 57.50
- NRO 52.22
- Support Level
- SGMT $8.05
- NRO $3.13
- Resistance Level
- SGMT $9.46
- NRO $3.19
- Average True Range (ATR)
- SGMT 0.65
- NRO 0.04
- MACD
- SGMT 0.07
- NRO 0.00
- Stochastic Oscillator
- SGMT 59.31
- NRO 82.22
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").